You Are Here:
Screening for and Management of Obesity in Adults
U.S. Preventive Services Task Force Recommendation Statement
Release Date: June 2012
The U.S. Preventive Services Task Force (USPSTF) makes recommendations about the effectiveness of specific clinical preventive services for patients without related signs or symptoms.
It bases its recommendations on the evidence of both the benefits and harms of the service, and an assessment of the balance. The USPSTF does not consider the costs of providing a service in this assessment.
The USPSTF recognizes that clinical decisions involve more considerations than evidence alone. Clinicians should understand the evidence but individualize decision making to the specific patient or situation. Similarly, the USPSTF notes that policy and coverage decisions involve considerations in addition to the evidence of clinical benefits and harms.
This Recommendation Statement was first published in Annals of Internal Medicine (Ann Intern Med 2012;26 June). Select for copyright and source information.
ContentsSummary of Recommendation and Evidence
Update of Previous Recommendation
Recommendations of Others
Members of the Task Force
|Task Force Ratings
Strength of Recommendations and Quality of Evidence
Summary of Recommendation and Evidence
The USPSTF recommends screening all adults for obesity. Clinicians should offer or refer patients with a body mass index (BMI) of 30 kg/m2 or higher to intensive, multicomponent behavioral interventions. This is a B recommendation.
The prevalence of obesity in the United States is high, exceeding 30% in adult men and women. Obesity is associated with such health problems as an increased risk for coronary heart disease, type 2 diabetes mellitus, various types of cancer, gallstones, and disability. These comorbid medical conditions are associated with higher use of health care services and costs among obese patients.
Obesity is also associated with an increased risk for death, particularly in adults younger than 65 years. The leading causes of death in obese adults include ischemic heart disease, diabetes, respiratory diseases, and cancer (for example, liver, kidney, breast, endometrial, prostate, and colon). Weight loss in obese individuals is associated with a lower incidence of health problems and death.
Body mass index is calculated from the measured weight and height of an individual. Recent evidence suggests that waist circumference may be an acceptable alternative to BMI measurement in some patient subpopulations. Screening tests were not a specific focus of this review.
Benefits of Detection and Early Intervention/Treatment
The USPSTF found adequate evidence that intensive, multicomponent behavioral interventions for obese adults can lead to an average weight loss of 4 to 7 kg (8.8 to 15.4 lb). These interventions also improve glucose tolerance and other physiologic risk factors for cardiovascular disease.
The USPSTF found inadequate direct evidence about the effectiveness of these interventions on long-term health outcomes (for example, death, cardiovascular disease, and hospitalizations).
Harms of Detection and Early Intervention/Treatment
Adequate evidence indicates that the harms of screening and providing behavioral interventions for obesity are no greater than small.
The USPSTF concludes with moderate certainty that screening for obesity in adults has a moderate net benefit. There is also benefit to offering or referring obese adults to intensive behavioral interventions to improve weight status and other risk factors for important health outcomes.
Patient Population Under Consideration
This recommendation applies to adults aged 18 years or older. The USPSTF uses the following terms to define categories of increased BMI: overweight is defined as a BMI of 25 to 29.9 kg/m2, and obesity is defined as a BMI of 30 kg/m2 or higher.
The USPSTF found that the most effective interventions were comprehensive and were of high intensity (12 to 26 sessions in a year). Although the USPSTF could not determine the effectiveness of other specific intervention components, most of the higher-intensity behavioral interventions included multiple behavioral management activities, such as group sessions, individual sessions, setting weight-loss goals, improving diet or nutrition, physical activity sessions, addressing barriers to change, active use of self-monitoring, and strategizing how to maintain lifestyle changes.
Weight-loss outcomes improved when interventions involved more sessions (12 to 26 sessions in the first year). Behavioral intervention participants lost an average of 6% of their baseline weight (4 to 7 kg [8.8 to 15.4 lb]) in the first year with 12 to 26 treatment sessions compared with little or no weight loss in the control group participants. A weight loss of 5% is considered clinically important by the U.S. Food and Drug Administration (FDA).
For obese patients with elevated plasma glucose levels, behavioral interventions decreased the incidence of diabetes diagnosis by about 50% over 2 to 3 years (number needed to treat, 7). Behavioral interventions also demonstrated some improvement in intermediate health outcomes, such as blood pressure, waist circumference, and glucose tolerance.
Interventions that combine pharmacologic agents (orlistat or metformin) with behavioral interventions resulted in weight loss and improvement in physiologic outcomes. Orlistat led to an average weight loss of about 2.6 kg (5.7 lb), a 1.9-cm decrease in waist circumference, and a decrease in fasting glucose level. However, there are concerns about the potential harms of orlistat because of recent FDA reports of rare severe liver disease and a lack of long-term safety data (1). Metformin led to a 1.5-cm greater decrease in waist circumference; however, its use for obesity is not approved by the FDA and is thus considered an off-label use. In addition, sufficient data were lacking about the maintenance of improvement after discontinuation of medications. As a result, the USPSTF is unable to recommend medication use.
Results of trials were not stratified by BMI category, making it difficult to ascertain the certainty of benefit in overweight (BMI of 25 to 29.9 kg/m2) groups. Although some studies included overweight participants, the mean BMI across trials was in the obese range (≥30 kg/m2). Therefore, the USPSTF was unable to examine differential effects of interventions on both overweight and obese patients. However, the recommended interventions may also lead to weight loss in some overweight patients. Compared with that of obesity, less is known about the association of overweight and long-term health outcomes.
No evidence was found regarding appropriate intervals for screening.
Although intensive interventions may be impractical within many primary care settings, patients may be referred from primary care to community-based programs for these interventions.
Research Needs and Gaps
Further research is needed to examine the direct effects of screening for obesity on long-term weight and health outcomes. More specific areas for further research include determining if weight-loss interventions lead to long-term weight loss and improvements in health outcomes. Studies are needed that reassess the best methods for screening in adults (for example, waist circumference or waist–hip ratio), address weight management in elderly adults and other subpopulations, and examine the cost-effectiveness of behavioral and pharmacologic interventions. Comparative effectiveness trials could provide more evidence about the components of an effective intervention.
Burden of Disease
Since 1976 to 1980, the prevalence of obesity and overweight in the United States have increased by 134% and 48%, respectively (2). In 2007 to 2008, 40% of men and 28% of women in the United States were overweight and 32% of men and 36% of women were obese. The prevalence of obesity exceeds 30% in most age- and sex-specific groups, with approximately 1 in 20 Americans having a BMI greater than 40 kg/m2 (3).
Depending on age and race, obesity has been shown to be associated with a 6- to 20-year decrease in life expectancy. The leading causes of death in obese adults include ischemic heart disease, diabetes, certain types of cancer (for example, liver, kidney, breast, endometrial, prostate, and colon), and respiratory diseases (4).
Scope of Review
To update its 2003 recommendation on screening for obesity and overweight in adults (5), the USPSTF reviewed the current state of the evidence and identified new evidence that addresses previously identified gaps. The USPSTF reviewed new evidence on the benefits and harms of screening and primary care–feasible or referable weight-loss interventions (6). The focus of this update was on nonsurgical interventions.
Accuracy of Screening Tests
In 2003, the USPSTF found adequate evidence that BMI is an acceptable measure for identifying adults with excess weight (5). Therefore, the USPSTF did not systematically address clinical screening tests for obesity and overweight in its review.
Effectiveness of Detection and/or Treatment
No new trials were identified that compared screening for obesity in adults with no screening. A total of 58 trials of weight-loss interventions were identified. Of these, 38 trials (13,495 participants) involved behavioral interventions, 18 trials (11,256 participants) involved orlistat plus behavioral interventions, and 3 trials (2652 participants) involved metformin plus behavioral interventions (4). In comparison with studies reviewed for the 2003 recommendation, there were 33 new trials of behavioral interventions, 16 new trials involving orlistat plus behavioral interventions, and 3 new trials involving metformin plus behavioral interventions (4).
Behavioral interventions. Behavioral intervention trials were generally of high quality, with 24% rated as good quality. Behavioral trial participants had mean BMIs ranging from 25 to 39 kg/m2, with an average baseline BMI across all trials of 31.9 kg/m2. Fifty-five percent of behavioral trials had participants with clinical or subclinical cardiovascular risk factors, such as impaired glucose tolerance (1).
Most of the trials showed that behavioral interventions had a statistically significant effect on weight loss at 12 to 18 months (6). Control group participants lost minimal or no weight, whereas intervention group participants lost 1.5 to 5 kg (3.3 to 11.0 lb), or 4% of baseline weight. Interventions with a greater number of sessions showed more weight loss. Patients who participated in 12 to 26 intervention sessions in the first year generally lost 4 to 7 kg (8.8 to 15.4 lb) (6% of baseline weight) compared with 1.5 to 4 kg (3.3 to 8.8 lb) (2.8% of baseline weight) in those who participated in fewer than 12 sessions (6).
An increased number of sessions, or increased treatment intensity, was associated with greater weight loss. Most higher-intensity interventions included self-monitoring, setting weight-loss goals, addressing barriers to change, and strategizing about maintaining long-term changes in lifestyle. However, which of these components was associated with weight loss could not be determined (6). A minimum of 12 sessions was essential to realize BMI reduction and maintenance.
Because direct data from screening trials on long-term health outcomes (for example, death, cardiovascular disease, and hospitalizations) were lacking, the USPSTF examined physiologic risk factors for cardiovascular disease. Two good-quality trials showed that diabetes incidence decreased by 30% to 50% over 2 to 3 years (number needed to treat, 7) with behavioral weight-loss interventions among overweight and obese patients with elevated plasma glucose levels (7, 8). Behavioral weight-loss interventions had a minimal effect on lipid outcomes and showed small reductions in blood pressure and waist circumference (6).
Combined pharmacologic and behavioral interventions. Fifty-five percent of behavioral trials and 57% of orlistat trials examined participants with clinical or subclinical cardiovascular risk factors. Metformin trials examined participants with diabetes risk factors (4).
Combined behavioral and pharmacologic (orlistat or metformin) interventions resulted in weight loss and improvement in physiologic outcomes. Orlistat led to an average weight loss of about 2.6 kg (5.7 lb), a 1.9-cm decrease in waist circumference, and a decrease in fasting glucose level. Metformin led to a 1.5-cm greater decrease in waist circumference; however, its use for obesity is not approved by the FDA and is thus considered an off-label use. In addition, the USPSTF found no evidence on the maintenance of improvement after discontinuation of medications (6).
Potential Harms of Detection and Intervention
Behavioral interventions. Possible harms of behavioral weight-loss interventions include decreased bone mineral density and increased fracture risk, serious injuries resulting from increased physical activity, and an increased risk for eating disorders. Although limited data suggest that weight loss may be associated with decreased bone density at the hip, the clinical significance of the bone loss is uncertain. The trials found no evidence that weight-loss interventions are associated with serious injuries or an increased risk for eating disorders, weight cycling, or depression (6).
Combined pharmacologic and behavioral interventions. There are concerns about the possible harms of orlistat because of recent FDA reports of severe liver disease and a lack of long-term safety data (9). Orlistat has recently been associated with possible kidney and pancreas damage, but no evidence was found supporting these potential harms (10). Both orlistat and metformin caused mild to moderate gastrointestinal adverse effects that resulted in medication discontinuation.
Estimate of Magnitude of Net Benefit
The USPSTF found adequate evidence that intensive, multicomponent behavioral interventions for obese adults can lead to weight loss, as well as improved glucose tolerance and other physiologic risk factors for cardiovascular disease. Inadequate evidence was found about the effectiveness of these interventions on long-term health outcomes (for example, death, cardiovascular disease, and hospitalizations). Adequate evidence indicates that the harms of screening and behavioral interventions for obesity are small. Therefore, the USPSTF concluded that the net benefit of screening is moderate.
Response to Public Comments
A draft of this recommendation statement was posted for public comment on the USPSTF Web site from 26 October to 23 November 2011. All comments received were reviewed during the creation of the final recommendation statement. Specifically, responses to these comments led to clarification of the definition of “intensive” and “multicomponent” in the Clinical Considerations and Discussion sections. The Implementation section was expanded to reflect referral to community-based programs. The Recommendations of Others section was expanded to include recommendations from other professional associations. The Clinical Considerations section was expanded to clarify why overweight was not included in the recommendation statement. The Scope of the Review section was refined to clarify the scope of the update. Some respondents asked about costs. The USPSTF does not consider costs in its appraisal of the effectiveness of a service.
Update of Previous USPSTF Recommendation
In 2003, the USPSTF recommended that clinicians screen all adult patients for obesity and offer intensive counseling and behavioral interventions to promote sustained weight loss in obese adults (B recommendation). The USPSTF concluded that the evidence was insufficient to recommend for or against the use of moderate- or low-intensity counseling together with behavioral interventions to promote sustained weight loss in obese adults (I statement) or the use of counseling of any intensity with behavioral interventions to promote sustained weight loss in overweight adults (I statement) (5). One change in the current recommendation is that the USPSTF found adequate evidence that intensive, multicomponent behavioral interventions for obese adults can also improve glucose tolerance and other physiologic risk factors for cardiovascular disease. Another change in the current recommendation is that it addresses only individuals with a BMI of 30 kg/m2 or higher; it does not address the effectiveness of screening in overweight adults with a BMI of 25 to 29.9 kg/m2. Although some studies included overweight patients, the differential effects of the interventions on overweight versus obesity could not be determined.
Recommendations of Others
The National Institutes of Health and the Canadian Task Force on Preventive Health Care recommend the use of BMI and waist circumference to screen adults for obesity. Both also recommend that weight-loss and weight-maintenance therapies should include a reduced-calorie diet, increased physical activity, and behavioral therapy. They also suggest considering the use of weight-loss medications as part of a multicomponent program in patients with a BMI greater than 27 kg/m2 and comorbid medical conditions (11, 12). The American Academy of Family Physicians has endorsed the USPSTF's recommendation on screening for obesity in adults (13). The American Congress of Obstetricians and Gynecologists recommends that the routine medical examination include an assessment of the patient's weight and BMI (14). It also recommends that clinicians consider referral for further evaluation and treatment whenever the resources are insufficient to meet the patient's needs, the patient has a BMI of 40 kg/m2 or higher, or the patient has a BMI of 35 kg/m2 or higher and comorbid medical conditions or has failed appropriate prior interventions (15).
Appendix: U.S. Preventive Services Task Force
Members of the U.S. Preventive Services Task Force at the time this recommendation was finalized* are Virginia A. Moyer, MD, MPH, Chair (Baylor College of Medicine, Houston, Texas); Michael L. LeFevre, MD, MSPH, Co-Vice Chair (University of Missouri School of Medicine, Columbia, Missouri); Albert L. Siu, MD, MSPH, Co-Vice Chair (Mount Sinai School of Medicine, New York, and James J. Peters Veterans Affairs Medical Center, Bronx, New York); Linda Ciofu Baumann, PhD, RN (University of Wisconsin, Madison, Wisconsin); Kirsten Bibbins-Domingo, PhD, MD (University of California, San Francisco, San Francisco, California); Susan J. Curry, PhD (University of Iowa College of Public Health, Iowa City, Iowa); Mark Ebell, MD, MS (University of Georgia, Athens, Georgia); Glenn Flores, MD (University of Texas Southwestern, Dallas, Texas); Adelita Gonzales Cantu, RN, PhD (University of Texas Health Science Center, San Antonio, Texas); David C. Grossman, MD, MPH (Group Health Cooperative, Seattle, Washington); Jessica Herzstein, MD, MPH (Air Products, Allentown, Pennsylvania); Joy Melnikow, MD, MPH (University of California, Davis, Sacramento, California); Wanda K. Nicholson, MD, MPH, MBA (University of North Carolina School of Medicine, Chapel Hill, North Carolina); Douglas K. Owens, MD, MS (Veteran Affairs Palo Alto Health Care System, Palo Alto, and Stanford University, Stanford, California); Carolina Reyes, MD, MPH (Virginia Hospital Center, Arlington, Virginia); and Timothy J. Wilt, MD, MPH (University of Minnesota Department of Medicine and Minneapolis Veteran Affairs Medical Center, Minneapolis, Minnesota). Former USPSTF members who contributed to the development of this recommendation include Ned Calonge, MD, MPH, and George Isham, MD, MS.
* Members of the Task Force at the time this recommendation was finalized. For a list of current Task Force members, go to http://www.uspreventiveservicestaskforce.org/members.htm.
- U.S. Food and Drug Administration. FDA Drug Safety Communication: Completed Safety Review of Xenical/Alli (Orlistat) and Severe Liver Injury. Rockville, MD: U.S. Food and Drug Administration; 2010. Accessed at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213038.htm on 23 May 2012.
- Stein CJ, Colditz GA. The epidemic of obesity. J Clin Endocrinol Metab. 2004;89:2522-5.
- Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010;303:235-41.
- LeBlanc E, O'Connor E, Whitlock EP, Patnode C, Kapka T. Screening for and Management of Obesity and Overweight in Adults. Evidence Synthesis No. 89. AHRQ Publication No. 11-05159-EF-1. Rockville, MD: Agency for Healthcare Research and Quality; October 2011.
- U.S. Preventive Services Task Force. Screening for obesity in adults: recommendations and rationale. Ann Intern Med. 2003;139:930-2.
- LeBlanc ES, O'Connor E, Whitlock EP, Patnode CD, Kapka T. Effectiveness of primary care–relevant treatments for obesity in adults: a systematic evidence review for the U.S. Preventive Services Task Force. Annals Intern Med. 2011;155:434-7.
- Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, et al; Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344:1343-50.
- Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346:393-403.
- U.S. Food and Drug Administration. Questions and Answers: Orlistat and Severe Liver Injury. Rockville, MD: U.S. Food and Drug Administration; 2010. Accessed at http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm213040.htm on 23 May 2012.
- Weir MA, Beyea MM, Gomes T, Juurlink DN, Mamdani M, Blake PG, et al. Orlistat and acute kidney injury: an analysis of 953 patients [Letter]. Arch Intern Med. 2011;171:703-4.
- National Heart, Lung, and Blood Institute. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults: the Evidence Report. Bethesda, MD: National Institutes of Health; 1998. Accessed at www.nhlbi.nih.gov/guidelines/obesity/ob_gdlns.pdf on 23 May 2012.
- Lau DC, Douketis JD, Morrison KM, Hramiak IM, Sharma AM, Ur E; Obesity Canada Clinical Practice Guidelines Expert Panel. 2006 Canadian clinical practice guidelines on the management and prevention of obesity in adults and children [Summary]. CMAJ. 2007;176:S1-13.
- American Academy of Family Physicians. Obesity. Leawood, KS: American Academy of Family Physicians; 2003. Accessed at www.aafp.org/online/en/home/clinical/exam/obesity.html on 23 May 2012.
- American College of Obstetricians and Gynecologists Committee on Gynecologic Practice. ACOG Committee Opinion No. 483: primary and preventive care: periodic assessments. Obstet Gynecol. 2011;117:1008-15.
- American College of Obstetricians and Gynecologists. Guidelines for Women's Health Care: A Resource Manual. 3rd ed. Washington, DC: American College of Obstetricians and Gynecologists; 2007.
Copyright and Source Information
Disclaimer: Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services.
Financial Support: The USPSTF is an independent, voluntary body. The U.S. Congress mandates that the Agency for Healthcare Research and Quality support the operations of the USPSTF.
Requests for Single Reprints: Reprints are available from the USPSTF Web site (www.uspreventiveservicestaskforce.org).
AHRQ Publication No. 11-05159-EF-2
Current as of June 2012
U.S. Preventive Services Task Force. Screening for and Management of Obesity in Adults: U.S. Preventive Services Task Force Recommendation Statement. AHRQ Publication No. 11-05159-EF-2. June 2012. http://www.uspreventiveservicestaskforce.org/uspstf11/obeseadult/obesers.htm